Literature DB >> 25471131

Haemarthrosis and arthropathy do not favour the development of factor VIII inhibitors in severe haemophilia A mice.

I Peyron1, J D Dimitrov, S Delignat, B Gangadharan, C Planchais, S V Kaveri, S Lacroix-Desmazes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25471131     DOI： 10.1111/hae.12579

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  4 in total

1.  Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Authors:  Y Dargaud; A Pavlova; S Lacroix-Desmazes; K Fischer; M Soucie; S Claeyssens; D W Scott; R d'Oiron; G Lavigne-Lissalde; G Kenet; C Escuriola Ettingshausen; A Borel-Derlon; T Lambert; G Pasta; C Négrier
Journal:  Haemophilia       Date:  2016-01       Impact factor: 4.287

2.  Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms.

Authors:  Maria T Georgescu; Paul C Moorehead; Alice S van Velzen; Kate Nesbitt; Birgit M Reipert; Katharina N Steinitz; Maria Schuster; Christine Hough; David Lillicrap
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

Review 3.  Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?

Authors:  Aditi Varthaman; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2018-12-04       Impact factor: 9.941

Review 4.  Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1.

Authors:  Davide Matino; Sajjad Afraz; George Zhao; Paul Tieu; Marco Gargaro; Francesca Fallarino; Alfonso Iorio
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.